Zealand Pharma A/S (ZEAL) Reports Phase 3 CV Safety; Plans Obesity Filings

Zealand Pharma (CSE:ZELA) reported a 70% increase in Q3 underlying loss to 685M DKK due to rising obesity drug R&D costs, with revenue dropping to 4M DKK. A one-off gain from royalty rights sale reduced net loss to 54M DKK. The company narrowed its 2026 operating cost forecast but kept revenue guidance at 4.5B DKK. Phase 2 trials for petrelintide showed promising weight loss and blood sugar reduction results.

Zealand Pharma reported Q3 2026 financials: revenue DKK 9.1B, net profit DKK 6.8B. Key updates: Phase 3 trial initiation for petrelintide, positive CHMP opinion for Zeydovio, and new research hub in Cambridge. Boehringer Ingelheim's survodutide showed promising results in obesity and type 2 diabetes trials.

Zealand Pharma (ZEAL.CO) reported positive Phase 1 trial results for ZP9830, an investigational Kv1.3 ion channel blocker. The trial showed favorable tolerability with no serious adverse events. The company plans further trials in plaque psoriasis and another autoimmune disease. ZEAL.CO shares are trading at DKK 221.50, down 2.12%.

Zealand Pharma and Generate Biologics will collaborate to develop multispecific drug candidates using AI. Zealand will pay $30 million upfront, with potential milestone payments up to $1.2 billion. Zealand will handle clinical development and commercialization, while Generate leads research. The partnership aims to address unmet medical needs in cardiometabolic diseases.

Zealand Pharma and Generate Biomedicines partnered to develop protein-based obesity treatments, with a deal potentially worth $1.2bn. Zealand will pay $30m upfront and milestones, while Generate uses its AI platform for research. Zealand handles clinical development and commercialization. Generate's tech has also attracted deals from Amgen and Novartis.

Generate Biomedicines and Zealand Pharma agreed to a $1.2B deal to develop protein-based treatments for metabolic diseases. Generate receives $30M upfront, with additional payments tied to milestones. Generate's shares rose 5% in extended trading. The companies will collaborate on two initial programs, with an option for a third. Zealand Pharma will handle clinical development and commercialization.